JPWO2020005877A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020005877A5
JPWO2020005877A5 JP2020572894A JP2020572894A JPWO2020005877A5 JP WO2020005877 A5 JPWO2020005877 A5 JP WO2020005877A5 JP 2020572894 A JP2020572894 A JP 2020572894A JP 2020572894 A JP2020572894 A JP 2020572894A JP WO2020005877 A5 JPWO2020005877 A5 JP WO2020005877A5
Authority
JP
Japan
Prior art keywords
methyl
thiazolo
benzothiazole
fluoro
indazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020572894A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021528466A (ja
JP7515415B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/038895 external-priority patent/WO2020005877A1/fr
Publication of JP2021528466A publication Critical patent/JP2021528466A/ja
Publication of JPWO2020005877A5 publication Critical patent/JPWO2020005877A5/ja
Priority to JP2024072881A priority Critical patent/JP2024105367A/ja
Application granted granted Critical
Publication of JP7515415B2 publication Critical patent/JP7515415B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020572894A 2018-06-27 2019-06-25 ハンチントン病を処置するためのヘテロアリール化合物 Active JP7515415B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024072881A JP2024105367A (ja) 2018-06-27 2024-04-26 ハンチントン病を処置するためのヘテロアリール化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862690540P 2018-06-27 2018-06-27
US62/690,540 2018-06-27
PCT/US2019/038895 WO2020005877A1 (fr) 2018-06-27 2019-06-25 Composés hétéroaryles pour le traitement de la maladie de huntington

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024072881A Division JP2024105367A (ja) 2018-06-27 2024-04-26 ハンチントン病を処置するためのヘテロアリール化合物

Publications (3)

Publication Number Publication Date
JP2021528466A JP2021528466A (ja) 2021-10-21
JPWO2020005877A5 true JPWO2020005877A5 (fr) 2022-06-21
JP7515415B2 JP7515415B2 (ja) 2024-07-12

Family

ID=67185796

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020572894A Active JP7515415B2 (ja) 2018-06-27 2019-06-25 ハンチントン病を処置するためのヘテロアリール化合物
JP2024072881A Abandoned JP2024105367A (ja) 2018-06-27 2024-04-26 ハンチントン病を処置するためのヘテロアリール化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024072881A Abandoned JP2024105367A (ja) 2018-06-27 2024-04-26 ハンチントン病を処置するためのヘテロアリール化合物

Country Status (12)

Country Link
US (1) US20210284660A1 (fr)
JP (2) JP7515415B2 (fr)
KR (1) KR20210038845A (fr)
CN (1) CN112805280A (fr)
AU (2) AU2019294482B2 (fr)
BR (1) BR112020026534A2 (fr)
CA (1) CA3104516A1 (fr)
EA (1) EA202092899A1 (fr)
IL (1) IL279714A (fr)
MX (1) MX2020014315A (fr)
SG (1) SG11202012869SA (fr)
WO (1) WO2020005877A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2879995T3 (es) 2015-12-10 2021-11-23 Ptc Therapeutics Inc Métodos para el tratamiento de la enfermedad de Huntington
WO2018226622A1 (fr) 2017-06-05 2018-12-13 Ptc Therapeutics, Inc. Composés permettant de traiter la maladie de huntington
EP3644996B1 (fr) 2017-06-28 2023-07-26 PTC Therapeutics, Inc. Procédés de traitement de la maladie de huntington
CA3067592A1 (fr) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. Methodes de traitement de la maladie de huntington
WO2019028440A1 (fr) 2017-08-04 2019-02-07 Skyhawk Therapeutics, Inc. Méthodes et compositions permettant de moduler l'épissageé
JP7399870B2 (ja) 2018-03-27 2023-12-18 ピーティーシー セラピューティクス, インコーポレイテッド ハンチントン病を処置するための化合物
WO2020005873A1 (fr) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Composés hétérocycliques et hétéroaryles pour le traitement de la maladie de huntington
US11685746B2 (en) 2018-06-27 2023-06-27 Ptc Therapeutics, Inc. Heteroaryl compounds for treating Huntington's disease
JP2022521467A (ja) 2019-02-05 2022-04-08 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングを調節するための方法および組成物
JP2022519323A (ja) 2019-02-06 2022-03-22 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングを調節するための方法および組成物
US11129829B2 (en) 2019-06-17 2021-09-28 Skyhawk Therapeutics, Inc. Methods for modulating splicing
US20240216369A1 (en) 2019-11-01 2024-07-04 Novartis Ag The use of a splicing modulator for a treatment slowing progression of huntington's disease
US20230322754A1 (en) * 2020-04-28 2023-10-12 Kymera Therapeutics, Inc. Irak inhibitors and uses thereof
TW202208358A (zh) 2020-05-13 2022-03-01 美商Chdi基金會股份有限公司 用於治療亨汀頓舞蹈症之htt調節劑
MX2023000167A (es) 2020-07-02 2023-05-03 Remix Therapeutics Inc Derivados de 5-[5-(piperidin-4-il)tieno[3,2-c]pirazol-2-il]indazol y compuestos relacionados como moduladores para el corte y empalme de ácidos nucleicos y para el tratamiento de enfermedades proliferativas.
IL299543A (en) 2020-07-02 2023-02-01 Remix Therapeutics Inc 2-(Indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as nucleic acid splicing modulators and for the treatment of multiple diseases
JP2024510487A (ja) * 2021-03-17 2024-03-07 エフ. ホフマン-ラ ロシュ アーゲー 新規なチアジアゾロピリミドン誘導体
EP4308576A1 (fr) * 2021-03-17 2024-01-24 F. Hoffmann-La Roche AG Nouveaux dérivés de thiazolopyrimidinone
EP4308572A1 (fr) * 2021-03-17 2024-01-24 F. Hoffmann-La Roche AG Nouveaux dérivés de thiénopyrimidinone
TW202304446A (zh) 2021-03-29 2023-02-01 瑞士商諾華公司 剪接調節子用於減慢杭丁頓氏舞蹈症進展的治療之用途
CN116262758A (zh) * 2021-12-15 2023-06-16 上海博悦生物科技有限公司 7-甲基噻唑并[5,4-d]嘧啶类化合物、制备方法及其用途
WO2023225244A1 (fr) * 2022-05-20 2023-11-23 Biogen Ma Inc. Composés hétérocycliques pour le traitement de la maladie de huntington

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004019002A2 (fr) * 2002-08-23 2004-03-04 The Board Of Trustees Of The Leland Stanford Junior University Glucosides fluorescents et leur procede d'utilisation
US7473784B2 (en) * 2005-08-01 2009-01-06 Bristol-Myers Squibb Company Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
CN101410385B (zh) * 2006-03-28 2011-08-24 高点制药有限责任公司 具有组胺h3受体活性的苯并噻唑类
US8153813B2 (en) * 2007-12-20 2012-04-10 Abbott Laboratories Benzothiazole and benzooxazole derivatives and methods of use
WO2009114874A2 (fr) * 2008-03-14 2009-09-17 Intellikine, Inc. Inhibiteurs de kinases (benzothiazole) et procédés d’utilisation associés
US20090258907A1 (en) * 2008-04-09 2009-10-15 Abbott Laboratories Compounds useful as inhibitors of rock kinases
WO2010024903A1 (fr) * 2008-08-29 2010-03-04 Yangbo Feng Benzo[d]oxazoles et benzo[d]thiazoles comme inhibiteurs de la kinase
US8283360B2 (en) * 2008-12-19 2012-10-09 Merck Sharp & Dohme Corp. Bicyclic heterocyclic derivatives and methods of use thereof
US8940716B2 (en) * 2010-05-06 2015-01-27 Bristol-Myers Squibb Company Bicyclic heteroaryl compounds as GPR119 modulators
EP2560008B1 (fr) * 2011-08-18 2016-11-30 Korea Institute of Science and Technology Compositions pharmaceutiques pour la prévention ou le traitement de maladies dégénératives des fonctions cérébrales et son procédé de criblage
CN107207526A (zh) * 2014-12-02 2017-09-26 拜耳作物科学股份公司 作为害虫防治剂的双环化合物
CN107635984B (zh) * 2015-03-11 2021-04-13 Fmc公司 杂环取代的二环唑杀有害生物剂
ES2879995T3 (es) * 2015-12-10 2021-11-23 Ptc Therapeutics Inc Métodos para el tratamiento de la enfermedad de Huntington
CN109071528B (zh) * 2016-03-11 2023-02-17 Ac免疫有限公司 用于诊断和治疗的双环化合物
US10526345B2 (en) * 2016-04-08 2020-01-07 Mankind Pharma Ltd. Compounds as GPR119 agonists
US10730868B2 (en) * 2016-07-14 2020-08-04 Bristol-Myers Squibb Company Bicyclic heteroaryl substituted compounds

Similar Documents

Publication Publication Date Title
JPWO2020005877A5 (fr)
JP7399869B2 (ja) ハンチントン病を処置するための化合物
JP2020522570A5 (fr)
JPWO2019191229A5 (fr)
JPWO2019191092A5 (fr)
AU2019203444B2 (en) Bicyclic lactams and methods of use thereof
JPWO2020005873A5 (fr)
CN114245794B (zh) 用于治疗亨廷顿氏病的化合物
KR101812357B1 (ko) Cdk4/6의 억제제로서의 피롤로피리미딘 화합물
HRP20210177T1 (hr) Supstituirani spojevi pirazolo[1,5-a]piridina kao inhibitori ret kinaze
JP2021503004A5 (fr)
JP2015504057A5 (fr)
JP2024105367A (ja) ハンチントン病を処置するためのヘテロアリール化合物
JP2014506929A5 (fr)
WO2020005882A1 (fr) Composés hétéroaryles pour le traitement de la maladie de huntington
HRP20151232T1 (hr) Derivati 2,3-dihidro-1h-inden-1-il-2,7-diazaspiro[3.6]nonana i njihova upotreba kao antagonista ili inverznih agonista grelinskog receptora
JP2011500774A5 (fr)
JP2015537010A5 (fr)
JP2015508075A5 (fr)
JP2011511034A5 (fr)
RU2015122895A (ru) Пуриновые ингибиторы человеческой фосфатидилинозит 3-киназы дельта
CA2649521A1 (fr) Nouveau compose de piperazine et son utilisation en tant qu'inhibiteur de la polymerase du vhc
IL297044A (en) Compounds for the treatment of Huntington's disease
JPWO2020231977A5 (fr)
JPWO2020065614A5 (fr)